1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Demographics of the 79 patients undergoing chordoma surgery in Beijing Tiantan Hospital between July 2012 and July 2016
Total MRT CDT P
No. of cases 79 39 40 
Tumor status
 Primary 37 24 13 .01
 Recurrent 42 15 27
Sex
 Male 43 21 22 .918
 Female 36 18 18
Age (mean) (yr)
 Primary 47.8 ± 17.4 42.3 ± 18.2 58.2 ± 9.97 .006
 Recurrent 47.1 ± 15.3 46.5 ± 16.5 47.6 ± 14.9 .828
 Total 47.5 ± 16.2 43.9 ± 17.5 51.0 ± 14.3 .050
Histopathology
 Conventional 71 35 36 1.000
 Chondroid 8 4 4
Blood supply^{^a}
 Rich 21 7 14 .073
 Not rich 55 31 24
Resection grade
 ≥90% 43 23 20 .423
 <90% 36 16 20
Survival status
 Alive 42 27 15 .018
 Died 26 8 18
 NA^{^b} 11 4 7
Presurgery radiation therapy
 Yes 17 5 12 .063
 No 62 34 28
Postsurgery radiation therapy
 Yes 30 14 16 .667
 No 43 21 22
 NA^{^c} 6 4 2
PFS (mo)^{^d} 40.3 ± 5.4 52.2 ± 5.7 18.7 ± 6.9 .003
OS (mo) 100.5 ± 7.1 113.9 ± 6.3 88.9 ± 9.3 .018
Note:—NA indicates not applicable.
↵a Operative notes on 3 cases showed no specified blood supply.
↵b Including both patients lost to follow-up and patients who did not die of chordomas.
↵c Including the patients whose radiation therapy information was not available.
↵d Patients without radiation therapy (n = 32).